Zhao Juan, Hong Haoyun, Zhai Joseph, Poudel Remy, Srivastava Sanjay, Stokes Andrew C, Lorkiewicz Pawel K, Jiang Tian, Robertson Rose Marie, Bhatnagar Aruni, Hall Jennifer L, Hamburg Naomi M, Keith Rachel J
American Heart Association, Dallas, United States.
American Heart Association Tobacco Regulation and Addiction Center, University of Louisville, Louisville, United States.
Tob Induc Dis. 2025 May 16;23. doi: 10.18332/tid/200649. eCollection 2025.
Volatile organic compounds (VOCs) are toxic compounds found in tobacco smoke. Despite research on cigarette generated single VOCs, scant evidence exists on the mixtures of VOCs associated with different tobacco products. We aimed to explore whether distinct VOC exposure profiles exist among users of combustible cigarettes, e-cigarettes, and non-users, and to assess their associations with cardiovascular (CV) health markers.
Participants who self-reported use of e-cigarettes, cigarettes, or no tobacco (n=348; mean age 26 ± 7 years) enrolled in The Cardiovascular Injury due to Tobacco Use (CITU) 2.0 study from July 2018 to July 2023 at two US sites (Boston, MA, and Louisville, KY). VOC metabolites were analyzed in urine one-hour post-use of a tobacco product via ultraperformance liquid chromatography. We applied unsupervised K-Means clustering on the creatinine-adjusted VOC metabolite data and explored the association between each cluster and blood pressure, adjusting for age, sex, and race.
The clustering analysis identified two distinct clusters. Cluster 1 (302 individuals, 86.8%) was characterized by low VOC metabolite levels with individuals predominantly e-cigarette users (59.3%), non-users (29.1%), and a smaller proportion of cigarette smokers (11.6%). Cluster 2 (46 individuals, 13.2%) had higher levels of VOC metabolites including CYMA, HPMMA, MHBMA3, and 3HPMA, and included most of the individuals who used cigarettes (91.3%). After adjustment for age, sex, and race, Cluster 2 was associated with a higher heart rate (β=3.29; 95% CI: -0.26-6.84; p<0.05) compared to Cluster 1. No significant differences were observed for systolic (β= -0.66; 95% CI: -4.60-3.28) or diastolic blood pressure (β=0.34; 95% CI: -2.51-3.2) between clusters.
These findings suggest that cigarette-induced VOC exposure may not impact cardiovascular function after acute exposure. Additionally, VOC exposure profiles vary across tobacco product types, suggesting that regulatory assessments of tobacco products could consider exposure patterns rather than product types. Clustering analyses may offer a powerful tool to assess the safety and risks of new and emerging tobacco products based on real-world exposure patterns.
挥发性有机化合物(VOCs)是烟草烟雾中发现的有毒化合物。尽管对香烟产生的单一挥发性有机化合物进行了研究,但关于与不同烟草产品相关的挥发性有机化合物混合物的证据却很少。我们旨在探讨可燃香烟使用者、电子烟使用者和非使用者之间是否存在不同的挥发性有机化合物暴露特征,并评估它们与心血管(CV)健康标志物的关联。
2018年7月至2023年7月期间,在美国的两个地点(马萨诸塞州波士顿和肯塔基州路易斯维尔)参加“烟草使用导致的心血管损伤(CITU)2.0”研究的参与者,他们自我报告使用电子烟、香烟或不使用烟草(n = 348;平均年龄26±7岁)。在使用烟草产品一小时后,通过超高效液相色谱法分析尿液中的挥发性有机化合物代谢物。我们对经肌酐校正的挥发性有机化合物代谢物数据应用无监督K均值聚类,并在调整年龄、性别和种族后,探讨每个聚类与血压之间的关联。
聚类分析确定了两个不同的聚类。聚类1(302人,86.8%)的特征是挥发性有机化合物代谢物水平较低,主要是电子烟使用者(59.3%)、非使用者(29.1%),以及较小比例的吸烟者(11.6%)。聚类2(46人,13.2%)的挥发性有机化合物代谢物水平较高,包括CYMA、HPMMA、MHBMA3和3HPMA,并且包括大多数使用香烟的个体(91.3%)。在调整年龄、性别和种族后,与聚类1相比,聚类2与较高的心率相关(β = 3.29;95%置信区间:-0.26 - 6.84;p < 0.05)。聚类之间的收缩压(β = -0.66;95%置信区间:-4.60 - 3.28)或舒张压(β = 0.34;95%置信区间:-2.51 - 3.2)未观察到显著差异。
这些发现表明,香烟引起的挥发性有机化合物暴露在急性暴露后可能不会影响心血管功能。此外,挥发性有机化合物暴露特征因烟草产品类型而异,这表明对烟草产品的监管评估可以考虑暴露模式而不是产品类型。聚类分析可能提供一个强大的工具,以基于实际暴露模式评估新兴烟草产品的安全性和风险。